Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Merck
Moodys
McKesson
Express Scripts

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Doxapram hydrochloride - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for doxapram hydrochloride and what is the scope of freedom to operate?

Doxapram hydrochloride is the generic ingredient in two branded drugs marketed by Hikma, Athenex Inc, and Watson Labs, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for doxapram hydrochloride. Two suppliers are listed for this compound.

Recent Clinical Trials for doxapram hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of FlorenceN/A
Beni-Suef UniversityN/A
Assiut UniversityPhase 1/Phase 2

See all doxapram hydrochloride clinical trials

Pharmacology for doxapram hydrochloride
Medical Subject Heading (MeSH) Categories for doxapram hydrochloride
Synonyms for doxapram hydrochloride
(+-)-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate
081D530
1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one hydrochloride
1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone hydrochloride hydrate
1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride monohydrate
1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one hydrochloride
1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one monohydrochloride
1-ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-onemonohydrochloride
113-07-5
113D075
2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, monohydrochloride
2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, monohydrochloride, monohydrate
2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-, monohydrochloride, monohydrate, (+-)-
2-Pyrrolidinone, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-, monohydrochloride
2-Pyrrolidinone, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-, monohydrochloride, monohydrate
2-Pyrrolidinone,3-diphenyl-, monohydrochloride
3,3-Diphenyl-1-ethyl-4-(2-morpholinoethyl)-2-pyrrolidinone hydrochloride
AC-4694
AC1L21NE
AHR 619
AHR-619
AKOS015906444
AOB5785
API0002485
AS-13336
C24H30N2O2
C24H30N2O2.HCl
CAS-113-07-5
CCG-101076
CCG-221205
CHEBI:59837
CHEMBL1200876
CPD000469229
CTK8F9367
Doxapram HCL
Doxapram hydrochloride [USAN:JAN]
Doxapram hydrochloride anhydrous
DSSTox_CID_27815
DSSTox_GSID_47837
DSSTox_RID_82579
DTXSID9047837
EINECS 204-022-3
FC1271
H927
J-002892
K-0985
LS-138812
MBGXILHMHYLZJT-UHFFFAOYSA-N
MCULE-1905124271
MLS001424142
MolPort-005-973-141
NC00326
NCGC00167459-01
NCGC00167459-02
NSC-170958
NSC170958
SAM001246792
SB18933
SCHEMBL40645
SMR000469229
Stimulexin
Tox21_112463
Tox21_112463_1

US Patents and Regulatory Information for doxapram hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Athenex Inc DOXAPRAM HYDROCHLORIDE doxapram hydrochloride INJECTABLE;INJECTION 076266-001 Jan 10, 2003 AP RX No No   Start Trial   Start Trial   Start Trial
Watson Labs DOXAPRAM HYDROCHLORIDE doxapram hydrochloride INJECTABLE;INJECTION 073529-001 Jan 30, 1992 DISCN No No   Start Trial   Start Trial   Start Trial
Hikma DOPRAM doxapram hydrochloride INJECTABLE;INJECTION 014879-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
Dow
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.